Ditching Slow-Growth, Costly Microarray Biz, Nanogen Seeks Buyer with ‘Deeper Pockets’

Last December it was GE Healthcare who pulled the plug on its CodeLink bioarray business, calling the platform unsuitable for clinical applications. Now it is Nanogen who has decided that the fabled array-based diagnostics market could materialize in the future, but not quickly enough to offset the high costs that are keeping the San Diego firm from reaching profitability.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.